In an amicus brief submitted to the Supreme Court, AAM called on the court to reject one form of patent system manipulation attempted by a brand-name drug company. AAM’s brief emphasizes the extent to which Helsinn’s interpretation of the on-sale bar would invite manipulation and foster confusion in the pharmaceutical market, with deleterious consequences for patients, taxpayers, and others who seek more affordable medicines.

View Brief

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.